It is one of the most common things women in their forties and fifties describe in consultations. Rosacea they had managed reasonably well for years, suddenly becoming significantly harder to control. Flushing that is more frequent and more intense. Redness that does not settle as quickly as it used to. Skin that has become reactive to things it previously tolerated. And, layered on top of all of this, the hot flushes that seem indistinguishable from a rosacea flare, because in many ways they are not distinguishable at all.

The relationship between rosacea and menopause is one of the most underrecognised and underdiscussed aspects of women’s skin health. Most women experiencing this pattern have never been told why it is happening. They have simply been told to manage their rosacea as before, often with approaches that are less effective now than they were a decade ago, because the hormonal context that influences the skin has fundamentally changed.

This post explains why rosacea worsens during perimenopause and menopause, what the research shows about oestrogen’s role in skin biology, and what can genuinely be done to help.

The skin changes of perimenopause and menopause are not cosmetic inconveniences. They are biological events with specific, manageable drivers. Understanding them is the first step to addressing them effectively.

Why Rosacea Is Primarily a Condition of Women in Middle Age

Rosacea is diagnosed significantly more often in women than in men. Based on articles retrieved from PubMed, a review published in the Journal of Midwifery and Women’s Health confirmed that rosacea is most commonly diagnosed in women aged between 30 and 50 years, coinciding with the perimenopausal and menopausal transition for many. [(DOI: 10.1111/j.1542-2011.2011.00156.x)](https://doi.org/10.1111/j.1542-2011.2011.00156.x)

This is not coincidence. The peak onset and peak severity of rosacea in women aligns closely with the period during which oestrogen levels become most variable and then decline. Understanding why oestrogen matters for skin biology explains why rosacea behaves differently during this transition, and why treatments that worked well in a woman’s thirties may need to be reconsidered in her forties and fifties.

What Oestrogen Does in the Skin

Oestrogen is one of the most biologically active hormones in skin tissue. Its effects are not limited to reproduction. It has receptors throughout the skin and plays an important regulatory role in barrier function, immune response, collagen synthesis, vascular tone and inflammatory signalling.

RESEARCH  |  Foundational Review Regulatory Roles of Sex Hormones in Cutaneous Biology and Immunology Kanda N, Watanabe S. J Dermatol Sci. 2005;38(1):1-7. Review from Teikyo University, Tokyo. Confirmed that oestrogen down-regulates production of pro-inflammatory chemokines by keratinocytes, suppresses antigen-presenting capacity while enhancing anti-inflammatory IL-10 production, prevents skin atrophy and dryness, enhances collagen synthesis, suppresses collagenolysis by reducing matrix metalloproteinase activity, maintains skin moisture and accelerates wound healing. These roles establish oestrogen as a key regulator of inflammatory and structural skin health. DOI: 10.1016/j.jdermsci.2004.10.011

For rosacea specifically, oestrogen’s anti-inflammatory and vascular regulatory roles are the most clinically significant. When oestrogen levels are stable, they help modulate the innate immune overactivity and vascular dysregulation that drive rosacea. When oestrogen levels decline or become erratic, those moderating influences are reduced. The inflammatory and vascular systems that are already prone to overreaction in rosacea become less regulated, and the skin becomes more reactive.

What Happens to Rosacea During Perimenopause

Perimenopause, the transitional period preceding menopause, is typically the most disruptive phase for rosacea-prone skin. Oestrogen levels during perimenopause are not simply declining. They are fluctuating unpredictably, sometimes spiking, sometimes dropping sharply, sometimes varying significantly from cycle to cycle. This hormonal variability is often more destabilising for rosacea than the lower but stable oestrogen levels of established menopause.

RESEARCH  |  Perimenopause and Skin 2026 Aesthetically Relevant Symptoms of Menopause Transition: Impact and Approach to Management Grone D, Fida M, de Oliveira GV, Kroumpouzos G. Clin Dermatol. 2026;44(2):348-355. Brown University Medical School and international collaborators. Specifically identified rosacea flares alongside hot flashes, worsening skin quality, dryness and increased wrinkling as established aesthetically relevant symptoms of perimenopause. Noted that the skin is particularly affected by the decline in 17-beta-oestradiol and DHEA alongside the increase in cortisol that accompanies the menopause transition. Emphasised that most of these findings, including rosacea flares, can be effectively managed. DOI: 10.1016/j.clindermatol.2026.01.009

During perimenopause, several things happen simultaneously that compound the rosacea picture. Oestrogen fluctuations reduce the anti-inflammatory modulation that has been protecting the skin. Cortisol levels often increase during this transition, adding a stress-hormonal component to inflammatory dysregulation. Sleep disruption, which is extremely common during perimenopause, increases systemic inflammation. And the vasomotor symptoms of perimenopause, the hot flushes and sweating episodes, are themselves vascular events that directly provoke the overactive vasculature driving rosacea.

Hot Flushes and Rosacea Flushing: The Overlap

This is one of the most clinically significant and least discussed aspects of menopausal rosacea. A menopausal hot flush is a vasomotor event: it involves sudden peripheral vasodilation, a surge of heat to the face and upper body, and often sweating as the body attempts to regulate its temperature. A rosacea flush is also a vasomotor event: it involves sudden dilation of the overreactive blood vessels in rosacea-affected skin in response to a trigger.

In women with rosacea going through perimenopause or menopause, these two events are not just happening simultaneously. They are compounding each other. Each hot flush is also a rosacea trigger. The vascular system that is already dysregulated in rosacea is being repeatedly provoked by the vasomotor events of menopause. The skin cannot recover between events in the way it might have done a decade earlier, because the oestrogen-mediated regulatory mechanisms that enabled that recovery have been reduced.

Many women in this situation find that their rosacea seems to have fundamentally changed in character, not just worsened in severity. They are right. It has changed, because the hormonal environment that was partially moderating it has changed.

RESEARCH  |  Consensus Expert Panel 2026 Aesthetic Treatment Considerations for the Perimenopausal and Menopausal Patient Fabi SG, Firsowicz M, Kamrani P, Draelos ZD, Dayan SH. J Cosmet Dermatol. 2026;25(1):e70626. Expert consensus roundtable including UCSD Medical Center and Duke University. Confirmed that oestrogen supports the extracellular matrix, collagen production and dermal blood supply, while progesterone promotes dermal blood supply and water retention. Decreased testosterone compounds this by impacting cutaneous blood supply and sebum production. Confirmed that numerous evidence-based therapies are available for perimenopausal and menopausal skin conditions. DOI: 10.1111/jocd.70626

Is your rosacea changing during perimenopause or menopause? A consultation at Face for Soul will assess what is driving the change and build a treatment plan that accounts for your hormonal picture. No referral needed. Book a Rosacea Consultation Read About the Full Rosacea Treatment Pathway

The Skin Barrier and Oestrogen Decline

One of the less visible but clinically important effects of oestrogen decline is on the skin barrier. Oestrogen maintains skin moisture by increasing hyaluronic acid and acid mucopolysaccharide levels in the dermis. It supports keratinocyte proliferation and suppresses epidermal atrophy. It enhances collagen synthesis and reduces collagenolysis. When oestrogen declines, the skin becomes drier, thinner, less hydrated and less structurally resilient.

For rosacea patients, a compromised barrier is not a cosmetic inconvenience. It is one of the primary mechanisms through which environmental triggers provoke the inflammatory and vascular cascade that drives rosacea. A weaker barrier means more triggers get through. More triggers mean more flares. More flares mean more barrier damage. The cycle accelerates during perimenopause unless it is actively interrupted through both treatment and appropriate skincare.

This is why barrier repair is even more critical for menopausal rosacea patients than it is for rosacea patients generally. Prescription skincare, mineral SPF and clinical-grade barrier support formulations are not optional adjuncts. They are central to the treatment plan.

What Actually Helps: The Treatment Approach at Face for Soul

The rosacea treatment plan for perimenopausal and menopausal patients is built on the same biological foundations as the standard rosacea pathway, with additional consideration of the hormonal context.

PRF: Calming the Inflammatory Burden

PRF (Platelet Rich Fibrin) uses your own growth factors to calm chronic inflammation and support barrier repair from within. For menopausal rosacea patients, where the inflammatory burden has increased due to hormonal change, PRF provides anti-inflammatory action that does not depend on oestrogen levels. It is not a hormone. It is your own biology. This makes it particularly valuable during hormonal transition when the oestrogen-mediated inflammatory modulation that previously helped regulate the skin is reduced.

Morpheus8: Addressing Vascular Dysregulation

The vascular dysregulation that drives rosacea redness and flushing is directly amplified during menopause by both oestrogen decline and vasomotor events. Morpheus8 radiofrequency microneedling addresses this at a structural level, reducing blood vessel density and VEGF activity in the dermis. For menopausal rosacea patients who have reached a point of relative skin stability, it is one of the most effective tools available for reducing persistent redness and flushing that has worsened during the hormonal transition.

Polynucleotides: Barrier and Cellular Repair

Polynucleotides trigger cellular repair and anti-inflammatory responses at a level that complements the barrier repair work that oestrogen decline has disrupted. For menopausal rosacea patients, they address one of the core consequences of hormonal change at a cellular level.

Prescription Skincare: The Daily Foundation

The skincare plan for menopausal rosacea needs to do two things simultaneously: reduce active inflammation and support the compromised barrier. Prescription-strength azelaic acid addresses the inflammatory component. Clinical-grade barrier repair moisturisers and mineral SPF address the structural vulnerability. As an independent prescriber, Vaiva can prescribe and supply formulations appropriate to this specific combination of needs.

A Note on Hormone Replacement Therapy

Hormone replacement therapy (HRT) is increasingly recognised as having beneficial effects on menopausal skin as well as systemic menopause symptoms. The expert consensus panel including UCSD and Duke University noted HRT among the most effective interventions for hormone-related skin changes in menopausal patients. The relationship between HRT and rosacea specifically is complex: HRT may help modulate some of the hormonal drivers of menopausal rosacea for some patients, while the oestrogen component may act as a trigger for others.

Discussion of HRT is part of the consultation for menopausal rosacea patients at Face for Soul where relevant, and where HRT is being considered or is already in use, the treatment plan is built around that context. Where specialist menopause medical input is appropriate, referral is offered.

What to Expect: Timeline and Realistic Outcomes

Menopausal rosacea typically takes longer to stabilise than rosacea in younger patients, because the hormonal context is continuing to change throughout the perimenopausal transition. The treatment plan needs to be adaptive, reviewed regularly, and built with realistic expectations.

Most patients see meaningful improvement in redness, flushing frequency and skin resilience over three to six months of structured treatment. The degree of improvement depends on the severity of the hormonal disruption to the skin, the condition of the barrier on presentation, and how consistently the daily skincare and SPF foundation is maintained.

The maintenance phase for menopausal rosacea is ongoing. The hormonal changes that have amplified rosacea are not temporary. The treatment plan needs to sustain and adapt over time rather than aiming for a fixed endpoint.

Rosacea and Menopause Consultations in Burford and Across the Cotswolds

Face for Soul is based at Castles Yard in Burford, Oxfordshire. The rosacea consultation at Face for Soul specifically addresses hormonal factors including perimenopause and menopause as part of building the treatment plan. Patients travel from Witney, Chipping Norton, Carterton, Oxford, Cheltenham, Cirencester and across the wider Cotswolds and Oxfordshire.

If your rosacea has changed significantly during perimenopause or menopause, or if previous treatments have become less effective and you have not understood why, a consultation is the right place to start.

Ready to address your rosacea in the context of your hormonal health? Book a consultation with Vaiva at Face for Soul in Burford or Chipping Norton. Prescription options available. No referral needed. Book Your Rosacea Consultation Shop Rosacea Skincare

[ BUTTON 1: Link to /consultation  |  BUTTON 2: Link to shop.faceforsoul.co.uk/collections/rosacea ]

References

1. Grone D, Fida M, de Oliveira GV, Kroumpouzos G. Aesthetically relevant symptoms of menopause transition: impact and approach to management. Clin Dermatol. 2026;44(2):348-355. https://doi.org/10.1016/j.clindermatol.2026.01.009

2. Fabi SG, Firsowicz M, Kamrani P, Draelos ZD, Dayan SH. Round table discussion: aesthetic treatment considerations for the perimenopausal and menopausal patient. J Cosmet Dermatol. 2026;25(1):e70626. https://doi.org/10.1111/jocd.70626

3. Kanda N, Watanabe S. Regulatory roles of sex hormones in cutaneous biology and immunology. J Dermatol Sci. 2005;38(1):1-7. https://doi.org/10.1016/j.jdermsci.2004.10.011

4. Fuller D, Martin S. Rosacea. J Midwifery Womens Health. 2012;57(4):403-409. https://doi.org/10.1111/j.1542-2011.2011.00156.x

5. Schaller M, et al. Exploring new dimensions in longitudinal rosacea management (REACH). Dermatol Ther (Heidelb). 2025;16(2):741-761. https://doi.org/10.1007/s13555-025-01612-x

All clinical citations retrieved from PubMed (pubmed.ncbi.nlm.nih.gov). Evidence retrieved June/July 2025.

Frequently Asked Questions

Q: Does rosacea get worse with menopause?

Yes, for many women. Oestrogen plays an important moderating role in skin barrier function, immune regulation and vascular tone. As oestrogen levels decline and fluctuate during perimenopause and menopause, the inflammatory and vascular systems driving rosacea become less regulated. Hot flushes compound this further by repeatedly triggering the overreactive blood vessels in rosacea-affected skin. A 2026 review published in Clinics in Dermatology by Kroumpouzos et al. specifically identified rosacea flares as an established symptom of the menopause transition.

Q: Why do I flush more with rosacea during menopause?

Menopausal hot flushes are vasomotor events involving sudden peripheral vasodilation. In women with rosacea, this vasomotor activity directly provokes the already overreactive blood vessels in the affected skin, causing a rosacea flush on top of the hot flush. The two events compound each other. Additionally, declining oestrogen reduces the vascular regulatory modulation that previously helped the skin recover between flushing episodes.

Q: Can rosacea treatment still work during menopause?

Yes. The treatments in the rosacea pathway at Face for Soul, including PRF, Morpheus8, polynucleotides and prescription skincare, work through biological mechanisms that do not depend on oestrogen levels. PRF uses your own growth factors to calm inflammation. Morpheus8 addresses vascular dysregulation at a structural level. These approaches can produce meaningful, lasting improvement even when the hormonal context has changed significantly.

Q: Should I mention my menopause symptoms at a rosacea consultation?

Yes, absolutely. The hormonal picture is directly relevant to understanding why your rosacea is behaving as it is and how to treat it most effectively. The consultation at Face for Soul specifically addresses hormonal factors including perimenopause and menopause as part of the treatment planning process. Whether you are on HRT, considering it, or not using it, all of this context informs the plan.

Q: Does HRT help with rosacea?

The relationship is complex and individual. HRT may help moderate some of the hormonal drivers of menopausal rosacea in some patients, given oestrogen’s regulatory role in skin barrier function, immune response and vascular tone. For other patients, the oestrogen component of HRT can act as a rosacea trigger. Discussion of HRT in the context of rosacea is part of the consultation at Face for Soul where relevant, and specialist menopause medical input is offered by referral where appropriate.

Q: My rosacea treatments stopped working during perimenopause. Why?

This is a very common experience and it has a clear biological explanation. Treatments that worked well in a hormonal environment supported by stable oestrogen levels may be less effective when that hormonal support has changed. The skin is behaving differently because its regulatory biology has changed. The treatment plan needs to be reassessed and adapted to the new context, rather than simply repeating approaches that were effective previously but are no longer sufficient.